Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble ...

Friedeberg brings more than 16 years of experience in economic development, having previously held leadership roles with the ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...

Globus Medical seems to be reverting to form, reporting a big jump in operating profit and profit margin for Q1, 2025. Here ...

Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst ...

(MENAFN- GlobeNewsWire - Nasdaq) AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected ...